CN103906508A - 治疗心血管疾病的方法 - Google Patents

治疗心血管疾病的方法 Download PDF

Info

Publication number
CN103906508A
CN103906508A CN201280052660.3A CN201280052660A CN103906508A CN 103906508 A CN103906508 A CN 103906508A CN 201280052660 A CN201280052660 A CN 201280052660A CN 103906508 A CN103906508 A CN 103906508A
Authority
CN
China
Prior art keywords
dosage form
metoprolol
pharmaceutical dosage
angiotensin
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280052660.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·M·科古勒
P·D·纳克哈特
A·古普塔
G·K·简恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of CN103906508A publication Critical patent/CN103906508A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201280052660.3A 2011-08-26 2012-08-23 治疗心血管疾病的方法 Pending CN103906508A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN2395MU2011 2011-08-26
IN2399/MUM/2011 2011-08-26
IN2395/MUM/2011 2011-08-26
IN2399MU2011 2011-08-26
IN2411/MUM/2011 2011-08-27
IN2411MU2011 2011-08-27
PCT/IB2012/054257 WO2013030725A1 (fr) 2011-08-26 2012-08-23 Procédés de traitement de troubles cardiovasculaires

Publications (1)

Publication Number Publication Date
CN103906508A true CN103906508A (zh) 2014-07-02

Family

ID=54289233

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280052660.3A Pending CN103906508A (zh) 2011-08-26 2012-08-23 治疗心血管疾病的方法

Country Status (12)

Country Link
US (1) US9446032B2 (fr)
EP (1) EP2747757A1 (fr)
JP (1) JP5898770B2 (fr)
KR (1) KR101708538B1 (fr)
CN (1) CN103906508A (fr)
AU (1) AU2012303683B2 (fr)
BR (1) BR112014004370A2 (fr)
CA (1) CA2846387C (fr)
MX (1) MX2014002163A (fr)
RU (1) RU2570752C2 (fr)
WO (1) WO2013030725A1 (fr)
ZA (1) ZA201401438B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622602A (zh) * 2016-01-30 2016-06-01 合肥华方医药科技有限公司 一种沙坦类小檗碱偶合物制备方法及其医药用途
CN105646512A (zh) * 2016-01-30 2016-06-08 合肥华方医药科技有限公司 一种列奈类小檗碱偶合物的制备及医药用途
CN105732612A (zh) * 2016-03-15 2016-07-06 合肥华方医药科技有限公司 一种普利类小檗碱偶合物的制备及医药用途
CN111024960A (zh) * 2019-12-27 2020-04-17 广州阳普医疗科技股份有限公司 用于高血压血样检测的添加剂、试剂盒和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103393620B (zh) * 2013-08-05 2016-02-03 青岛市中心医院 一种阿折地平胶囊剂及其制备方法
ES2950154T3 (es) 2014-05-19 2023-10-05 Chiesi Farm Spa Nanopartículas de clevidipino y composiciones farmacéuticas de las mismas
CN104173312A (zh) * 2014-05-30 2014-12-03 广西博科药业有限公司 一种含有非洛地平和美托洛尔盐的缓释片及其制备方法
UA122224C2 (uk) 2015-03-03 2020-10-12 Саніона А/С Комбінована композиція тезофензину і бета-блокатора
WO2016155815A1 (fr) * 2015-04-01 2016-10-06 Ceva Sante Animale Forme posologique orale solide d'amlodipine et usages vétérinaires correspondants
AU2017297812A1 (en) * 2016-07-13 2019-02-07 Assistance Publique - Hopitaux De Paris Meclozine derivatives and diclazuril derivatives for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes
EA028561B1 (ru) * 2016-12-28 2017-11-30 Тева Фармасьютикал Индастриз, Лтд. Твердые лекарственные формы тадалафила
EA034975B1 (ru) * 2018-03-13 2020-04-13 Владимир Александрович Горшков-Кантакузен Способ лечения лабильной и пароксизмальной гипертензии
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
EP3578164A1 (fr) 2018-06-05 2019-12-11 Bio-Gate AG Composition thixotrope
US20220160658A1 (en) 2019-01-07 2022-05-26 Saniona A/S Tesofensine for reduction of body weight in prader-willi patients
CN209673136U (zh) 2019-05-07 2019-11-22 深圳市华普森电子有限公司 高清智能一体化管道探测器
MX2022013236A (es) 2020-04-22 2023-01-24 Saniona As Tratamiento de la obesidad hipotalamica.
CN111870685B (zh) * 2020-07-16 2022-11-29 上海市同仁医院 运动相关多肽在制备防治缺血性心脏病药物中的应用
WO2023175573A1 (fr) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Compositions pharmaceutiques comprenant un bêta-bloquant et un inhibiteur de sglt2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
WO2007010501A2 (fr) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant une combinaison d'un beta-bloquant et d'un inhibiteur d'ace
CN101249083A (zh) * 2008-03-21 2008-08-27 北京润德康医药技术有限公司 一种含有氨氯地平和美托洛尔的复方缓释制剂及制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4046889A (en) 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
US4466972A (en) 1977-06-20 1984-08-21 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them
JPS55301A (en) 1978-02-14 1980-01-05 Yamanouchi Pharmaceut Co Ltd 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
SE429652B (sv) 1978-06-30 1983-09-19 Haessle Ab 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
JPS57171968A (en) 1981-04-17 1982-10-22 Kyowa Hakko Kogyo Co Ltd 1,4-dihydropyridine derivative
GB2111978B (en) 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
JPS6058233B2 (ja) 1982-05-24 1985-12-19 田辺製薬株式会社 ２−オキソイミダゾリジン誘導体及びその製法
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US4772596A (en) 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
DE3829398A1 (de) * 1988-08-30 1990-03-08 Rentschler Arzneimittel Fixe arzneimittelkombination mit verzoegerter freisetzung
US5185351A (en) 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
WO1999018957A1 (fr) 1998-03-26 1999-04-22 Reddy-Cheminor, Inc. Composition pharmaceutique stable contenant du besylate d'anilodipine et de l'atenolol
CA2434436A1 (fr) * 2001-01-26 2002-08-01 Teddy Kosoglou Combinaisons d'inhibiteur(s) de l'absorption de sterols et d'agents cardio-vasculaires pour le traitement d'affections vasculaires
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
CN101351195A (zh) * 2005-11-18 2009-01-21 阿库布莱克科技公司 分段的药物剂量形式
US8815285B2 (en) 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
WO2008023869A1 (fr) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. PRÉPARATION PHARMACEUTIQUE COMBINÉE À LIBÉRATION CONTRÔLÉE COMPRENANT DES INHIBITEURS CALCIQUES À BASE DE DIHYDROPYRIDINE ET DES INHIBITEURS DE HMG-CoA RÉDUCTASE
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
BRPI0907650A2 (pt) * 2008-01-25 2015-07-21 Torrent Pharmaceuticals Ltd Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc
WO2011028016A2 (fr) 2009-09-04 2011-03-10 한올바이오파마주식회사 Préparation pharmaceutique comprenant des agents bêtabloquants et des agents bloquants du récepteur de l'angiotensine ii
CN102145000A (zh) * 2010-02-06 2011-08-10 赤峰维康生化制药有限公司 一种坎地沙坦酯和美托洛尔复方制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
WO2007010501A2 (fr) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant une combinaison d'un beta-bloquant et d'un inhibiteur d'ace
CN101249083A (zh) * 2008-03-21 2008-08-27 北京润德康医药技术有限公司 一种含有氨氯地平和美托洛尔的复方缓释制剂及制备方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105622602A (zh) * 2016-01-30 2016-06-01 合肥华方医药科技有限公司 一种沙坦类小檗碱偶合物制备方法及其医药用途
CN105646512A (zh) * 2016-01-30 2016-06-08 合肥华方医药科技有限公司 一种列奈类小檗碱偶合物的制备及医药用途
CN105732612A (zh) * 2016-03-15 2016-07-06 合肥华方医药科技有限公司 一种普利类小檗碱偶合物的制备及医药用途
CN111024960A (zh) * 2019-12-27 2020-04-17 广州阳普医疗科技股份有限公司 用于高血压血样检测的添加剂、试剂盒和应用
CN111024960B (zh) * 2019-12-27 2023-02-17 广州阳普医疗科技股份有限公司 用于高血压血样检测的添加剂、试剂盒和应用

Also Published As

Publication number Publication date
RU2570752C2 (ru) 2015-12-10
CA2846387C (fr) 2016-02-09
US20140302125A1 (en) 2014-10-09
RU2014111474A (ru) 2015-10-10
KR101708538B1 (ko) 2017-02-20
NZ621666A (en) 2015-02-27
WO2013030725A1 (fr) 2013-03-07
KR20140053337A (ko) 2014-05-07
BR112014004370A2 (pt) 2017-03-21
US9446032B2 (en) 2016-09-20
JP5898770B2 (ja) 2016-04-06
JP2014525433A (ja) 2014-09-29
MX2014002163A (es) 2014-09-25
ZA201401438B (en) 2015-06-24
EP2747757A1 (fr) 2014-07-02
CA2846387A1 (fr) 2013-03-07
AU2012303683B2 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
CN103906508A (zh) 治疗心血管疾病的方法
TWI407978B (zh) 濕粒狀藥物之製備方法
AU2012303683A1 (en) Methods for treating cardiovascular disorders
KR20140101391A (ko) 심혈관 질환의 치료 방법
JP2010505943A (ja) 時間治療理論に基づく循環器疾患の治療用組合せ製剤
CN102065847A (zh) 含有血管紧张素-ⅱ受体阻断剂的药物制剂
JP6068765B2 (ja) 薬学的複合製剤
KR20090114328A (ko) 약제학적 제제
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
WO2003005967A2 (fr) Formulation a liberation double comportant un ester ethylique de levodopa et un inhibiteur de decarboxylase dans une couche a liberation instantanee avec un ester ethylique de levodopa et un inhibiteur de decarboxylase dans un noyau a liberation controlee
JP2019529486A (ja) カンデサルタンおよびアムロジピンを含む単一層からなる複合製剤
JP6151854B2 (ja) 心血管疾患の治療用経口製剤
CN106163518A (zh) 包含血管紧张素‑Ⅱ受体阻断剂和HMG‑CoA还原酶抑制剂的药物复合制剂
CN106390126A (zh) 含有沙坦类药物和NEPi的药物组合物
WO2019130277A1 (fr) Formulations pharmaceutiques d'azilsartan médoxomil
US20110123612A1 (en) Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
TW201201800A (en) A pharmaceutical controlled release composition of losartan
KR20110129405A (ko) 약제학적 제제
KR20090107954A (ko) 약제학적 제제
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
US20100008956A1 (en) Composition and combinations of carboxylic acid losartan in dosage forms
NZ621666B2 (en) Methods for treating cardiovascular disorders
NZ625998B2 (en) Methods for treating cardiovascular disorder
JPWO2008078728A1 (ja) アスコルビン酸含有医薬組成物
JP2014231491A (ja) 制御放出ペレットからなる薬学的組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140702

WD01 Invention patent application deemed withdrawn after publication